Levocabastine

CHEMBL1615438 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

420.5 g/mol

LogP

2.5

Phase

4

A selective H1 antihistamine available as eye drops or nasal spray for treating allergic conjunctivitis and rhinitis. It provides rapid and long-lasting relief from itching, redness, and other allergy symptoms.

Moleküler Ağırlık

420,5000 g/mol

LogP

2,50

TPSA

64,30 Å²

Lipinski RO5

Geçer

Etki Mekanizması

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1

InChI

InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23-,25-,26-/m1/s1

Molecular Formula

C26H29FN2O2

HBD / HBA

1 / 5

Döndürülebilir Bağlar

4

Ağır Atomlar

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A selective H1 antihistamine available as eye drops or nasal spray for treating allergic conjunctivitis and rhinitis. It provides rapid and long-lasting relief from itching, redness, and other allergy symptoms.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Levocabastine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1615438. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 54385. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Levocabastine PillFYI'da

Yapı

Hızlı Veriler

Formül: C26H29FN2O2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Levocabastine

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget